Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 43 Stomach Neoplasms 42 Rectal Neoplasms 28 Pancreatic Neoplasms 17 Lymphoma, Large B-Cell, Diffuse 13 Colonic Neoplasms 13 Cholangiocarcinoma 11 Neoplasm Metastasis 10 Adenocarcinoma 10 Neoplasms 9 Carcinoma, Hepatocellular 8 Carcinoma, Non-Small-Cell Lung 7 Biliary Tract Neoplasms 7 Locally Advanced Rectal Cancer 6 Gastrointestinal Neoplasms 6 Gallbladder Neoplasms 6 Esophageal Neoplasms 6 Adenocarcinoma Of Esophagus 6 Peritoneal Neoplasms 5 Recurrence 4 Ovarian Neoplasms 4 Esophageal Squamous Cell Carcinoma 3 Carcinoma 3 Bile Duct Neoplasms 3 Appendiceal Neoplasms 3 Advanced Solid Tumors 3 Advanced Solid Tumor 3 Pathologic Complete Response 2 Melanoma 2 Lymphoma, Non-Hodgkin 2

Interventions

Temozolomide 1 S 1 (combination) 1 Oxaliplatin 1 Nivolumab 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Pan-tumor × Oxaliplatin × Clear all

NCT04566380 2025-06-03

ONO-4538 Phase II Rollover Study (ONO-4538-98)

Ono Pharmaceutical Co., Ltd.

Phase 2 Recruiting

Pan-tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡